No retraction, correction or concern found when last checked on Oct 17, 2026.

The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities

Christiana M. Neophytou, Myrofora Panagi, Triantafyllos Stylianopoulos and 1 more

Cancers · 2021 · Review · CC BY

doi:10.3390/cancers13092053

Abstract

Simple Summary. Metastasis, the process by which cancer cells escape primary tumor site and colonize distant organs, is responsible for most cancer-related deaths. The tumor microenvironment (TME), comprises different cell types, including immune cells and cancer-associated fibroblasts, as well as structural elements, such as collagen and hyaluronan that constitute the extracellular matrix (ECM). Intratumoral interactions between the cellular and structural components of the TME regulate the aggressiveness, and dissemination of malignant cells and promote immune evasion. At the secondary site, the TME also facilitates escape from dormancy to enhance metastatic tumor outgrowth. Moreover, the ECM applies mechanical forces on tumors that contribute to hypoxia and cancer cell invasiveness whereas also hinders drug delivery and efficacy in both primary and metastatic sites. In this review, we summarize the latest developments regarding the role of the TME in cancer progression and discuss ongoing efforts to remodel the TME to stop metastasis in its tracks.

Abstract. The tumor microenvironment (TME) regulates essential tumor survival and promotion functions. Interactions between the cellular and structural components of the TME allow cancer cells to become invasive and disseminate from the primary site to distant locations, through a complex and multistep metastatic cascade. Tumor-associated M2-type macrophages have growth-promoting and immunosuppressive functions; mesenchymal cells mass produce exosomes that increase the migratory ability of cancer cells; cancer associated fibroblasts (CAFs) reorganize the surrounding matrix creating migration-guiding tracks for cancer cells. In addition, the tumor extracellular matrix (ECM) exerts determinant roles in disease progression and cancer cell migration and regulates therapeutic responses. The hypoxic conditions generated at the primary tumor force cancer cells to genetically and/or epigenetically adapt in order to survive and metastasize. In the circulation, cancer cells encounter platelets, immune cells, and cytokines in the blood microenvironment that facilitate their survival and transit. This review discusses the roles of different cellular and structural tumor components in regulating the metastatic process, targeting approaches using small molecule inhibitors, nanoparticles, manipulated exosomes, and miRNAs to inhibit tumor invasion as well as current and future strategies to remodel the TME and enhance treatment efficacy to block the detrimental process of metastasis.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

1Metastasis is responsible for more than 90% of cancer mortality; however, the underlying mechanisms driving this multistep process, ranging from local invasion at the primary site to the outgrowth of metastatic cells at the secondary sites, remain elusive. The communication between the neoplastic cells and the adjacent stromal cells begins at the earliest stages of tumor formation and continues during primary growth, local invasion, intravasation and establishment at the secondary site. While it was initially established that genetic aberrations are predominantly responsible for tumor initiation and progression, it has become clear during the last two decades that the tumor microenvironment (TME) plays an equally important role in modulating the aggressiveness, motility, dissemination, and colonization of cancer cells to distal organs. The TME comprises the extracellular matrix (ECM) and basement membrane (BM), endothelial cells, adipose cells, tumor-infiltrating immune cells, cancer-associated fibroblasts (CAFs), neuroendocrine cells, pericytes, as well as a plethora of signalling molecules that regulate tumor progression. Cancer cells secrete growth factors and cytokines (including IL-6, IL-1β, TGF-β1, TGF-β2, FGF-2, and PDGF) that recruit and reprogram stromal cells, such as immune cells and fibroblasts, as well as enzymes that degrade and remodel the surrounding ECM and BM, such as matrix metalloproteinases (MMPs). In this review, we summarize the latest findings in the efforts for understanding the complex roles of TME constituents in various stages of metastatic progression and discuss about strategies as well as future challenges for targeting TME components to battle the most aggressive forms of the disease.

2.1. Role of Immune Cells in Modulating Cancer Metastasis

2It is unambiguously accepted that immune cells exert pivotal effects in the properties of cancer cells at different stages of the invasion-metastasis cascade, either by infiltrating the tumor or by affecting the systemic environment. During every step of this lethal process, cancer cells are being exposed to the immune system which attacks them to restrain their growth. These anti-tumor effects are primarily mediated by CD8+ T cells as well as natural killer (NK) cells, which have been shown to restrict metastatic outgrowth of tumor cells, whereas their depletion enhances metastasis without affecting primary tumor growth. However, during tumor evolution, cancer cells develop strategies not only to avoid immune surveillance but also to induce systemic responses by exploiting types of immune cells, such as myeloid cells, in order to enhance their metastatic efficiency.

3The main type of myeloid cells implicated in regulating metastasis are macrophages, which are derived by hematopoietic stem cells (HSC) in the bone marrow and considered “professional” antigen presenting cells (APCs). They present foreign antigens to helper T cells and can prime naïve T cells. Macrophages are recruited to the tumor site via chemokines produced from cancer and stromal cells and are, thus, referred to as tumor-associated macrophages (TAMs). TAMs can act in two opposing functions depending on their polarization subtype: M1-type TAMs have pro-inflammatory and anti-tumoral properties and activate the immune system by releasing interferon (IFN)-γ and IL-12. On the other hand, M2-type TAMs are pro-tumorigenic, and exert immunosuppressive functions by producing IL-10, induce angiogenesis and stimulate tumor cells to release MMPs that favor cancer progression by disrupting the ECM and BM.

4TAMs enable metastasis at various stages of the process, including activation of epithelial-to-mesenchymal transition (EMT), local invasion, and intravasation into the blood stream, transfer of cancer cells through the circulation, extravasation, and seeding at the secondary site, and finally promotion of survival and outgrowth of cancer cells at distant organs. They achieve this by secreting numerous chemokines, inflammatory molecules, and growth factors that promote metastatic progression.

5At the primary tumor site, TAMs help create a suitable microenvironment that allows tumor invasion. The term “tumor microenvironment of metastasis” (TMEM) is proposed to describe the close arrangement of cancer cells, perivascular TAMs, and endothelial cells often located at sites of intravasation. Increased TMEM density in breast carcinoma patient samples positively correlates with increased risk of distant organ metastases. During EMT, growth factors and cytokines, including TGF-β, Wnt, and EGF, can lead to the activation of an orchestrated transcriptional program during which tumor cells lose epithelial characteristics and gain mesenchymal features leading to increased capacity for invasion and metastasis. Inflammation-induced EMT has also been reported and TAMs appear to play an important role in this transition. In hepatocellular carcinoma (HCC), TAMs are recruited by cancer cells by expressing glypican and secrete TGF-β, PDGF, VEGF, chemokine (C-C motif) ligand 2 (CCL2), and M-CSF. In the tumor microenvironment, TAMs secrete many cytokines such as TGF-β and IL-6 that can induce EMT. In pancreatic cancer, M2-polarized TAMs expressing Toll-like receptor 4 (TLR4) promoted EMT via TLR4/IL-10 signaling. Specifically, TAMs upregulated mesenchymal markers vimentin and snail, induced MMP-2 and MMP-9 proteolytic activity and diminished E-cadherin levels, leading to increased fibroblastic morphology, proliferation, and migration of pancreatic cancer cells. TAMs exhibiting a CD68+HLA−DR+ surface marker phenotype can induce migration of HCC cells via the NF-κB/FAK pathway. TAMs can further facilitate the invasiveness of cancer cells induced by phosphatase of regenerating liver (PRL-3), a marker of colorectal cancer (CRC) liver metastasis. CRC cells also produce PRL-3 and tumor necrosis factor-α (TNF-α) that increase the expression of intermediate-conductance Ca2+-activated potassium (KCNN4) channels in TAMs; KCNN4 induce the secretion of IL-6 and IL-8 by TAMs and improve CRC cell invasiveness. In addition, TAMs can release CCL18 chemokine that can stimulate angiogenesis and promote tumor progression in breast cancer. In addition to their role in regulating migration and invasion of primary tumor cells, TAMs also mediate crucial functions on cancer cells disseminated at secondary tissues.

6The term “metastasis-associated macrophages” (MAMs) is proposed to describe the role of macrophages that have infiltrated at the metastatic site. MAMs are essential for the extravasation of circulating tumor cells (CTCs) and their successful outgrowth at the secondary site, partly through VEGF expression. The expression of CCL2 and the infiltration of the tumor site by macrophages have been correlated with metastatic disease in breast cancer. MAMs that originate from inflammatory monocytes (IMs), are recruited to secondary sites along with monocytes expressing the CCR2 receptor. The stroma, as well as the tumor itself, are responsible for attracting these cells at the metastatic site by expressing CCL2. CCR2 activation following binding to CCL2 in MAMs, induces the secretion of the chemokine ligand CCL3 by macrophages at the metastatic site; this enables the retention of macrophages at the lung and increases the number of lung metastatic foci, whereas inhibition of CCR1, the receptor of CCL3, may have therapeutic implications in breast cancer lung metastasis. Moreover, vascular cell adhesion molecule-1 (VCAM-1) expressed in breast cancer cells has been associated with lung metastasis relapse. Following infiltration of breast cancer cells to the leukocyte-rich microenvironment of the lung, VCAM-1 provides a survival advantage by tethering MAMs to cancer cells via counter-receptor α4 integrins.

2.2. Role of Mesenchymal Stem Cells in Regulating Metastasis

7Mesenchymal stem (or stromal) cells (MSCs) are multipotent stem cells that reside in many adult tissues, such as the bone marrow, adipose tissue, liver, lung, periosteum, muscle connective tissue, and spleen. They are important for generating and repairing skeletal tissues, such as cartilage and bone. MSCs reside in most tumors and significantly influence the development and function of the TME. These cancer-associated MSC (CA-MSC) are reprogrammed by the tumor to exert pro-tumorigenic functions, such as enhancing EMT, promoting angiogenesis and metastasis.

8Importantly, MSCs facilitate metastases by secreting exosomes which interact with cancer cells to affect their proliferation and migration. They are the only type of cells that can mass produce exosomes. Exosomes derived from MSCs are microvesicles (60–200 nm size) that have a phospholipid bilayer carrying proteins, lipids, miRNAs and mRNA. They act in a paracrine fashion and can be detected in various body fluids. In a breast cancer model, treatment with MSC-exosomes led to an enhanced migratory ability, through increased β-catenin levels and activation of WNT pathway target genes, Axin2 and Dkk1. Gastric cancer tissue-related mesenchymal stem cells (GC-MSCs), excrete exosomes carrying miRNAs that following delivery into gastric cancer cells can promote gastric cancer metastasis. Particularly, the expression of miR-221 was significantly increased and correlated with enhanced local invasion, advanced tumor-node-metastasis stage, and lymphatic metastasis. Overall, the presence of MSC-derived exosomes induced an EMT program and promoted migration and invasion of HGC-27 gastric cancer cells. Bone marrow-derived mesenchymal stem cells (BM-MSCs), can also promote the migration of multiple myeloma cells by producing exosomes which selectively carry cytokines, such as chemotactic proteins MCP-1, MCP-2, MCP-3, 40 SDF-1, 41,42, and IGF-1.

9Contradicting to these reports, MSCs were also found to suppress metastatic tumor growth through their excreted exosomes carrying different strands of miRNAs. MSCs that interact with disseminated breast cancer cells in the bone marrow during the early stages of dissemination, promote cancer cell dormancy and enable an extended period of cycling quiescence in which cancer cells are maintained in G0/G1 phase of the cell cycle. MSCs that produce exosomes with increased miR-23b and decreased MARCKS expression suppress cell cycle and promote dormancy of metastatic breast cancer cells.

2.3. Cancer-Associated Fibroblasts in Promoting Metastasis

10CAFs constitute one of the most abundant stromal components in solid tumors. CAFs are distinguished from different cell subtypes based on the presence of several stromal markers, including integrin β1 (CD29), fibroblast activation protein (FAP), and α-smooth muscle actin (α-SMA). CAFs can be derived from different cell types of the TME: local fibroblasts that undergo mesenchymal–mesenchymal transition (MMT), epithelial cells via epithelial-to-mesenchymal transition (EMT), endothelial cells following endothelial-to-mesenchymal transition (endMT), bone marrow originated from hematopoietic stem cells or mesenchymal stem cells and adipocytes. Cancer cells can activate fibroblasts in a three-step process: recruitment, transformation to CAFs, and maintenance in the TME. Following their activation, CAFs release signaling molecules to favor the survival of cancer cells and promote the recruitment and transformation of other cell types within the TME. CAFs facilitate remodelling of the ECM by releasing collagen and fibronectin, producing MMPs, and increasing VEGF levels. This leads to the re-organization of the matrix, creating tracks which neoplastic cells exploit to directionally migrate, accompanied by CAFs.

11The presence of a specific subset of CAFs in the microenvironment, CAF-S1, was recently shown to suppress the immune system by attracting and promoting the survival, differentiation, and activation of CD4+CD25+ T lymphocytes. In addition, in women with primary tumors smaller than 2 cm without lymph node metastasis, the presence of CAF-S1 cells favors breast cancer metastasis to the bone via CDH11/osteoblast cadherin.

2.4. Endothelial Cells Attract Cancer Cells to the Metastatic Site

12The lymphatic vessels that support the tumor at the secondary site are lined with loosely-connected lymphatic endothelial cells (LECs) that may also promote metastasis. LECs recruit tumor cells by producing chemoattractants, such as CCL21 and SDF-1, which bind to CCR7 and CXCR4 receptors expressed in cancer cells, respectively. Tumors developing at secondary organs produce factors that condition LECs to facilitate with cancer cell recruitment, extravasation, and outgrowth. One example is the secretion of IL-6 by tumor cells that leads to STAT3 activation in LECs and subsequently high VEGF expression. The expression of VEGF induced by tumor cells has been associated with the activation of HIF-1 in LECs, suggesting that tumor-secreted factors may support and direct lymphatic metastasis.

2.5. Components in the Blood Microenvironment That Facilitate Metastasis

13During their dissemination throughout the body, circulating tumor cells (CTCs) encounter other cell types and factors in the peripheral blood that facilitate not only their survival but also their metastatic ability. These include various components, such as platelets, immune cells, cytokines, and circulating tumor microemboli (CTMs), which interact with CTCs and promote their survival. Metastatic tumor cells can induce platelet adhesion and aggregation through the production of platelet activators such as ADP, thrombin, thromboxane, and von Willebrand factor. Platelets enable the survival of cancer cells during their transit within the blood circulation and their colonization at the secondary site. Platelets are a major source of lysophosphatidic acid (LPA), a natural lysophospholipid, which can bind to six different G-protein coupled receptors (GPCRs—LPA1-6 receptors) expressed on eukaryotic cells and activate multiple intracellular signaling pathways involved in cell survival, proliferation, differentiation, motility, cytoskeleton rearrangement and cytokine secretion. Tumor cells induce platelet aggregation and production of LPA. Autotaxin (ATX), a lysophospholipase D also produced and released in platelet α-granules, is responsible for the basal concentration of LPA in blood. LPA interacts with different GPCRs found on cancer cells and promotes metastasis. The presence of certain cytokines in serum, including IL-17A, has also been correlated with increased number of CTCs and metastatic burden.

3.1. Role of the ECM in Cancer Metastasis

14Similar to stromal cells, the non-cellular component of the TME, the ECM, exerts determinant roles in tumor progression and metastasis. ECM is defined as a network of extracellular proteins and other macromolecules, including collagen, fibronectin, hyaluronan, elastin, integrins, microfibrillar proteins, and proteoglycans that provide structural and biochemical support to the tissue. ECM is present at the BM and interstitial space and regulates cell proliferation, differentiation, and tissue homeostasis. Under pathological conditions like tumorigenesis, it functions as a biological barrier restraining tumor cells from proliferating and metastasizing. However, during tumor progression, ECM is remodeled and transformed into a metastasis-promoting microenvironment. Such structural rearrangements involve the excessive production of collagen in the interstitial matrix and subsequent development of fibrosis, a hallmark of many desmoplastic tumors. This fibrotic response predominantly occurs due to TGF-β-mediated activation of CAFs, which are the major drivers of collagen synthesis. Fibrosis involves not only upregulation of collagen but also Lysyl oxidase (LOX)-induced cross-linking of collagen fibers further causing tumor stiffening. Individuals with high mammographic density (i.e., a greater accumulation of connective tissue to fat) are in greater risk for breast cancer development. Furthermore, the differentially stiffened stroma combined with tumor cell overpopulation in a physically restricted area impose the development of compressive mechanical forces within the tumor, known as solid stress. It has been estimated in humans that this growth-induced solid stress can be as high as 142.4 mmHg (19.0 kPa). Cancer cells respond to stiffness and mechanical compression by undergoing actomyosin and cytoskeleton contraction facilitating the formation of traction forces on their surroundings. Tumor cells become hyper-responsive to these matrix compliance cues, which are propagated intercellularly via mechanosensors, such as integrin-ECM complexes, growth factors and p130-associated proteins. Upon stimulation, mechanosensors transduce the signal to focal adhesion signaling molecules including small Rho-GTPases, FAK, SRC, paxillin, and RAS GTPase to activate downstream signaling cascades to promote malignancy. In pancreatic cancer, solid stress can either activate fibroblasts or directly act on pancreatic cancer cells to promote migration via the GDF15-Akt pathway. Moreover, mechanical compression facilitates migration of glioblastoma cells by inducing Mek1/Erk1 signaling. Overall, tumors possessing a dynamic stiffened ECM are often highly metastatic and correlate with poorer patient outcome.

3.2. Hypoxic Microenvironment as a Major Driver of Cancer Metastasis

15Solid stress and tumor stiffening contribute to metastasis not only by increasing directly the invasive and metastatic potential of cancer cells but also by inducing hypoxia. Specifically, the acquisition of solid stress can largely deform the surrounding tissue and compress or even collapse intratumoral lymphatic and blood vessels resulting in poor perfusion. Tumor cells which have been deprived of oxygen and nutrients trigger the expression of pro-angiogenic factors such as VEGF, to induce the de novo formation of blood vessels ensuring the adequate supply of O2 and nutrients to the tumor. However, these “neovessels” are tortuous and leaky. The lack of intercellular junctions between endothelial cells and poor pericyte coverage foster an uneven distribution of blood flow. Consequently, in response to local hypoxia, the protein levels of hypoxia inducible factors (HIFs) increase and play a major role in regulating this process by promoting the survival of cancer cells under hypoxic conditions. HIF is a heterodimeric transcription factor comprised of HIF-1α or HIF-2α and HIF-1β subunits. HIF interacts with its co-activator CBP/p300, and binds to hypoxia response elements located in target gene promoters to activate them.

16During hypoxia, cancer cells change their metabolic activities by switching from oxidative phosphorylation to aerobic glycolysis which causes acidification of the extracellular space. Acidosis is a major physiological parameter of TME linked to hypoxia which allows the survival of selected cells that can adapt to these acidic conditions. As tumor cells undergo rapid rounds of proliferation, the energy consumption dramatically increases resulting in oxygen deprivation. To meet the biosynthetic requirements, tumors shift into aerobic glycolysis, known as Warburg effect, whereby glucose is converted into lactate, followed by lactic acid fermentation in the cytosol. The excess of lactate is then released in the TME along with other acidic materials, establishing an acidic environment. Importantly, the pH of tumors can decrease to 5.7 compared to the pH of healthy tissues which is 7.4. This pH reduction is even more striking in the lysosomes and endosomes, where it ranges from 4.5 to 5.5 and, thus, may interfere with the activity of therapeutic agents which utilize these structures for their intracellular transport.

17Induction of hypoxia activates a vicious circle of downstream signaling cascades to promote responses that define cancer hallmarks, including metabolic reprogramming, mesenchymal transformation of cells, proliferation, survival, angiogenesis, migration, invasion, immunosuppression, and metastasis. Approximately 50–60% of solid tumors exhibit hypoxic regions where O2 tension can be low (<10 mmHg) and heterogeneously distributed within the tumor. Hypoxia affects the TME and puts selective pressure on cancer cells that develop genetic and/or epigenetic adaptive changes in order to survive and in combination with the formation of new vessels, mainly at the tumor periphery, eventually metastasize to distant sites.

4.1. TAMs as a Promising Target against Cancer Metastasis

18Targeting TAMs at the primary site has been a promising approach to combat metastatic disease. As described above, the presence of TAMs at the primary tumor site has been correlated with progressive disease and metastasis. Specifically, these cells enable EMT and help cancer cells escape towards the circulation. To block this metastasis enabling step, the role of JWH-015, a cannabinoid receptor 2 (CB2) agonist previously shown to suppress lung cancer progression, was investigated. JWH-105 inhibited EMT in non-small cell lung cancer cells (NSCLC) by suppressing ERK and STAT-3 activation and EGFR signaling; in addition, JWH-105 reduced invasiveness of A549 cells when co-cultured with M2 macrophages, by downregulating the expression of FAK, VCAM1, and MMP-2. The effects of the inhibitor were also confirmed using a syngeneic mouse model, where it blocked tumor growth in vivo and inhibited macrophage recruitment and EMT at the primary tumor. TAMs are recruited to the tumor site by colony-stimulating factor-1 (CSF-1/M-CSF) to enhance their survival, differentiation and proliferation. CSF-1 is a potent macrophage chemoattractant produced by cancer cells to recruit macrophages expressing the CSF-R1 receptor and polarizes them towards the M2-tumor promoting subtype. Blocking CSF/CSFR interaction inhibits the pro-tumoral activities of TAMs and their ability to promote metastasis (Figure 1).

19Macrophages can also be targeted at the secondary metastatic site using chemical molecules. Liposomal encapsulation of clodronate (dichloromethylene diphosphonate), a bisphosphonate that acts by targeting osteoclasts and cancer cells, has been used to treat bone metastasis. In addition, treatment with clodronate-liposomes is a well-established method for macrophage ablation. The inhibition of metastasis by clodronate-liposomes may, therefore, be attributed to the depletion of osteoclasts precursors as well as TAMs. A distinct macrophage subpopulation (CD11b+Gr1−), was found to mediate extravasation and outgrowth of breast cancer cells to the lung. Treatment with liposomes bearing clodronate significantly reduced the number of tumor cells in murine lungs. Using mice bearing lung tumors, liposomal delivery of clodronate was also shown to reduce the number of monocytes in peripheral blood and of macrophages in tumors, and to inhibit bone and muscle metastasis. In a sorafenib-resistant tumor model, lung metastasis was inhibited following photoimmunotherapy targeting TAMs. Moreover, dequalinium-14, an anti-tumor agent, was effective in reducing TAM motility and infiltration of irradiated tumors and blocked metastasis in a locally irradiated mouse model of CRC.

20As previously mentioned, TAMs fuel cancer cells with pro-angiogenic factors within the TME to facilitate metastasis. One of the major factors that induce angiogenesis secreted by TAMs is MMP-9 that promotes the vascular development in avascular tumors and enables tumor cell intravasation. However, targeting MMPs to reduce metastasis with the use of bisphosphonates has shown limited efficacy in pre-clinical and clinical studies. The ability of TAMs to induce angiogenesis in tumors by secreting VEGF into the TME, was blocked in an in vivo model of gallbladder cancer, by intratumorally injecting IFN-γ. IFN-γ can inhibit the differentiation of monocytes to the tumor-promoting M2 macrophages in the TME, can switch TAMs from M2 into M1 subtype, blocking their ability to secrete VEGF. The polarization of TAMs to the M2 phenotype can also be blocked by Luteolin which inhibits the IL4-mediated activation of STAT6, reduces the expression of M2-associated genes and suppresses TAM-secreted CCL2 to inhibit migration of Lewis lung carcinoma cells. Finally, blocking the interaction of prostate cancer cells and TAMs, inhibited their proliferation, migration, and invasion as well as tumor growth in vivo.

4.2. Exploiting Cancer-Associated Mesenchymal Stroma/Stem-Like Cells to Control Metastasis

21As discussed above, MSCs that associate with tumors excrete exosomes that carry components that affect the TME to promote or inhibit metastasis. MSCs can also be manipulated to deliver anti-cancer drugs to the tumor site. In one study, several human MSC populations were treated with sub-lethal concentrations of taxol and exosomes carrying this drug were isolated. These taxol-loaded exosomes displayed enhanced cytotoxicity in cancer cell lines in vitro. Systemic intravenous administration of MSC-derived taxol-loaded exosomes in vivo significantly reduced the growth of subcutaneous primary highly metastatic MDA-hyb1 breast tumors. Importantly, the treatment also led to a significant reduction of distant metastases in the lung, liver, spleen, and kidney. Moreover, MSCs loaded with paclitaxel strongly inhibited lung metastasis of murine melanoma.

22In addition, MSCs delivering miR-124 and miR-145 synthetic mimics to co-cultured glioma cells significantly decreased their migration by targeting SCP-1 and Sox2 genes, respectively. MSCs producing exosomes that deliver the synthetic miR-143 to osteosarcoma cells can significantly reduce their migration. Manipulated therapeutic stem cells encapsulated in biodegradable, synthetic extracellular matrix (sECM) that could release tumor-selective S-TRAIL, eliminated tumor cells in a glioblastoma mouse model and significantly prolonged animal survival.

4.3. Targeting the Blood Microenvironment

23Functional blocking of platelet activity leads to inhibition of cancer cell metastasis. Anti-platelet drugs have been explored in cancer treatment. Resting platelets are activated by ADP produced by cancer cells. APT102, an ADPase that can block platelet function, was able to disrupt bone metastasis in mice when combined with aspirin. In addition, blocking the LPA/ATX signaling axis has been shown to be effective against metastasis. Treatment of animals with the BMP22 ATX inhibitor, inhibited cancer cell colonization to the bone. In addition, taking advantage of the interaction of platelets with CTCs may be a promising therapeutic approach against metastasis. Genetically modified platelets that express TRAIL can significantly eliminate the tumor cells in vitro and suppress metastasis in a prostate cancer mouse model.

24Regulating the cytokine content of peripheral blood may also help reduce tumor burden. IL-17A, a pro-inflammatory cytokine, has emerged as a critical factor in enhancing breast cancer metastasis. The systemic neutralization of IL-17A significantly reduces breast cancer metastasis in mice by reducing expression of CXCL12/SDF-1 in the metastatic niches. When cancer cells pass through organs with high levels of the chemokine SDF-1/CXCL12, they exit circulation and extravasate. The ablation of IL-17A and treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF) causes a decline in the number of CTCs and decreased metastasis in mice (Figure 1). GM-CSF administration polarized the TAMs toward the M1 phenotype, elevated the number of CD4+ and CD8+ T lymphocytes and NK cells and eliminated CTCs.

5. Strategies to Improve Tumor Oxygenation and Therapeutic Efficacy

25As described above, the dense ECM and the solid stress applied in desmoplastic tumors contribute to metastasis not only by increasing directly the invasive and metastatic potential of cancer cells but also by inducing hypoxia and hindering drug delivery owing to hypo-perfusion caused by vessel compression. There are two main strategies to overcome these physiological abnormalities of the TME: (i) the vascular remodeling and (ii) the stroma normalization strategy.

5.1. Remodeling the Tumor Vasculature

26In contrast to vascular disruption, the vascular normalization strategy involves the restoration of a functional vasculature that closely resembles the normal and is mediated by increasing the pericyte coverage of endothelial cells, limiting leakiness of blood vessels and, thus, increasing tumor perfusion and oxygenation. This approach alleviates the geometric obstruction against blood flow and re-establishes the balance between pro- and anti-angiogenic signaling. A classical therapeutic target of vascular normalization is VEGF signaling, which is upregulated in most tumors. Bevacizumab, the first approved anti-angiogenic drug, and its derivatives are currently used for the treatment of metastatic CRC. Bevacizumab interacts with soluble VEGF preventing receptor binding. To avoid tumor acquired resistance, these anti-angiogenic drugs are used in combination with tyrosine receptor kinases inhibitors (e.g., sorafenib, and sunatinib) acting downstream in the signaling cascade or as cocktail (e.g., with Herceptin). An alternative therapeutic approach is the application of anti-angiogenic peptides like thrombospondin (TSP), endostatin, coagulation peptides, growth factors and chemokines, all having a high success rate in clinical trials due to their low toxicity and high specificity for their receptors. Many studies have demonstrated that pre-treatment of tumors with VEGF signaling inhibitors improves delivery of both intermediate and large-size nanoparticles (NPs) by inducing vascular normalization, increasing the expression of MMPs and degradation of collagen fibers and, thus, potentiating drug penetration. However, not all cancer types are benefited by the vascular normalization strategy. For instance, the less permeable and compressed vasculature of desmoplastic tumors may not exhibit the expected normalization phenotype. Vessel density, anti-angiogenic drug dose, and treatment intervals are important factors influencing therapeutic outcome. Additionally, reduction in vessel pore size may hamper large NPs from entering the tumor stroma. Therefore, alternative strategies applied alone or in combination with vascular normalization should be considered to improve treatment outcomes.

5.2. Stroma Normalization Strategy to Target Hypoxia

27Apart from promoting metastasis, the dense ECM can act as a physical barrier to the penetration of immune cells within the TME, creating an immune-excluded phenotype. Furthermore, the compression of intratumoral vessels owing to tumor stiffening and solid stress elevation can cause an inefficient and heterogeneous distribution of blood flow in the tumor resulting in insufficient and non-uniform delivery of drugs and immune cells to the tumor and hypoxia, which can further support tumor progression and metastasis. Importantly, increased ECM density and vessel compression have been recently observed not only in the primary tumors but also in breast cancer metastasis in the lungs and has been related to compromised therapeutic efficacy in lung metastatic lesions. Therefore, the stroma normalization strategy aims to restore vessel functionality by alleviating intratumoral solid stresses and reducing tumor stiffness, which allows for increased tumor perfusion and suppresses invasion and metastasis. There are two routes to stroma normalization by: (a) CAF reprogramming and (b) ECM remodeling.

28Targeting CAFs as an intratumoral solid stress alleviation approach, has yielded promising results. Although highly heterogenic, CAFs are generally divided into myofibroblastic and non-myofibroblastic populations across different cancer types. Myofibroblastic CAFs are responsible for ECM deposition contributing to tissue stiffness directly through the production of collagen and proteoglycans, while non-myofibroblasts are implicated in inflammatory signaling. Importantly, targeting CAFs and associated responses by sonic hedgehog signaling inhibition has shown to reduce solid stress and IFP in tumor models, enhancing the activity of cytotoxic agents like taxol and 5′-fluorouracil (5′-FU). However, this strategy has failed in clinical trials and preclinical studies have shown that excessive depletion of CAFs might fuel tumor progression. In addition to their role in solid stress accumulation, CAFs along with other stromal components promote the establishment of an immunosuppressive TME via the release of various immunosuppressive ligands such as TGF-β, CXCL12, IL-6, CXCL-1, G-SCF, and others which can impede intratumoral cytotoxic T cell infiltration and activity and enhance the recruitment of MDSCs, neutrophils and M2-like TAMs. The production of TGF-β by CAFs, allows invasive cancers to evade immune system surveillance by excluding T-cells from the microenvironment. Concurrent treatment with therapeutic antibodies that inhibit the programmed death-1 (PD-1)–programmed death-ligand 1 (PD-L1) pathway and TGFβR1 kinase inhibitor, galunisertib, led to increased recruitment of CD8+ T cells to the liver colonized with CRC cells and reduced metastatic burden. In addition, combined targeting of TGF-β and PD-1/PD-L1 blockade reduced overall metastatic burden and caused complete tumor eradication in the majority of treated animals. Similarly, in patients with metastatic urothelial cancer, concurrent targeting of the TGF-β and PD-1/PD-L1 axis led to increased T cell infiltration and significant anti-tumor response.

29Regarding ECM remodeling, several studies have focused on modifying the two most abundant ECM components of desmoplastic tumors, collagen, and hyaluronan. Targeting the ECM using monoclonal antibodies against TGF-β (ID11) as well as known antihypertensive drugs have been found to potentiate the distribution and efficacy of therapeutics. A well-characterized example is the angiotensin II type I receptor inhibitor, losartan. Preclinical studies evaluating the effect of losartan in pancreatic and breast tumor models have demonstrated that losartan suppresses TGF-β signaling resulting in a subsequent downregulation of collagen I and hyaluronan synthesis and other downstream fibrotic factors, alleviating solid stress and IFP, all of which leading to enhanced vascular perfusion, improved efficacy of drugs and reduced metastasis (Figure 2). The potential of losartan to modulate the tumor microenvironment and improve cancer therapy has been already shown in clinical trials in combination with chemoradiation in locally advanced pancreatic tumors. Safety concerns have been raised, though, regarding the use of antihypertensive agents in cancer patients experiencing normal blood pressure or hypotension. Hence, additional approved agents have been repurposed for priming the TME including antihistamine drugs (e.g., tranilast), corticosteroids (e.g., dexamethasone), anti-inflammatory (e.g., pirfenidone), anti-diabetic drugs (e.g., metformin), and other agents possessing anti-fibrotic effects (e.g., pentoxifylline), vitamin D, and relaxin.

6. Discussion—Future Perspectives

30Currently, the development of novel therapeutic approaches for treating metastatic tumors specifically by remodeling the TME, is focused on combination studies, as monotherapies have had limited success in the clinic. Special attention is given on the concurrent modulation of the immune system. One example is anti-CD40 agonistic antibody therapy that involves CD8+ T cell-priming and T cell-mediated anti-tumor responses. CD40 agonists bind to the CD40 receptor, a cell-surface member of the TNF receptor superfamily, expressed by APCs, including dendritic cells; once activated, dendritic cells activate T cells and prime them against tumors. Even though local or systemic administration of anti-CD40 treatment was shown to slow post-surgical metastatic growth in mice, it has performed moderately in pre-clinical studies. In the TME, tumors and tumor-associated macrophages (TAMs) secrete immunosuppressive factors, such as the checkpoint modulator PD-L1, which diminish the cytotoxic functions of tumor-specific CD8+ T cells. A recent study showed that in metastatic ductal pancreatic adenocarcinoma (PDAC) patients, the concurrent treatment with agonistic CD40 antibodies and anti-PD-1 treatment, can trigger effective T cell immunity. In addition, the presence of Toll-like Receptors (TLRs) expressed in macrophages and other cells in the TME can provide immunosuppressive tumor protection. Treatment with TLR agonists, in combination with anti-PD-1 therapy, suppresses the growth of primary and metastatic tumors. Treatment with the TLR7 agonist increases the M1/M2 TAMs ratio and increases recruitment of activated CD8+ T cells in the TME in a mouse model of metastatic head and neck squamous cell carcinoma (HNSCC).

31Novel combination studies also include nanotherapeutics against metastasis. Current strategies developed to modulate the TME using NPs, include modifying tumor vasculature permeability, polarizing macrophages towards the M1 phenotype, affecting CAFs and stromal components modulating tumor hypoxia. Gold nanoparticles (AuNPs), exhibiting low toxicity, can remodel the TME and may be used either with targeted therapeutics or conventional chemotherapy drugs. AuNPs induce tumor vasculature normalization, increase blood perfusion, minimize hypoxia in melanoma tumors, and suppress lung metastasis.

32In addition to manipulating the tumor vasculature and stroma to improve oxygenation, targeting other factors that contribute to the development of hypoxia in the TME were also found to effectively block metastasis. In most solid tumors, hypoxia causes the production of carbonic anhydrase (CAIX). CAIX is involved in pH regulation, causes acidification of the tumor microenvironment leading to reduced cell adhesion, increased motility and migration, induction of neovascularization, and activation of proteases. Expression of CAIX is a poor prognostic marker in patients with metastatic cancer. Since CAIX is implicated in regulating both extracellular and intracellular pH, targeting its enzymatic activity with specific pharmacological inhibitors is a logical approach against metastasis. The efficacy of sulfamate CAIX inhibitors has been shown in in vitro and in vivo models of breast metastasis as well as in clinical Phase I/II trials. Inhibition of CAIX using small molecule inhibitor AAZ can slow tumor growth, inhibit metastasis, and eliminate tumor stem cells in mice. Therefore, combination strategies targeting cancer cell-derived molecules under hypoxic conditions along with TME remodeling agents which promote tumor oxygenation could be exploited as promising therapeutic approaches.

33The experimental models utilized to study anti-metastatic therapy should also be revisited to include important TME components that seem to affect patient therapeutic outcomes. Metastasis-on-a-chip devices that house multiple bioengineered three-dimensional (3D) organoids can be used for the evaluation of therapeutic approaches against metastatic potential of cancer cells. A recent study showed that CRC cells specifically homed to liver and lung constructs, similarly to the clinical setting. Moreover, novel 3D metastasis-on-a-chip model, which includes organ-specific extracellular microenvironment mimicking the progression of kidney cancer cells metastasizing to the liver, can be used to compare the efficacy of various therapeutic strategies.

34In vivo metastasis models using immunosuppressed mice lack the important component of the immune system needed to fully characterize the therapeutic efficacy of a potential TME-modulating drug. Currently, substantial effort is being made to create humanized patient-derived xenograft (PDX) mouse models, for example using CD34+ HSCs, which more accurately recapitulate human immune responses. The next generation of PDX mice will involve engraftment with a human immune system and are expected to be a valuable tool for assessing therapeutic approaches for metastatic tumors.

35While developing therapeutics to target the metastatic process by modulating the TME, considerations should also be taken regarding the differences between the microenvironment at the primary and secondary tumor sites. In a recent paper discussing the differences between the TME at the breast and following metastasis to the brain, it was highlighted that the tissue of origin, such as lung, breast, or melanoma, determines the type of TME to be developed at the secondary site and how this will regulate metastatic outgrowth. Evidence suggests that malignant cells facilitate metastasis by bringing their own soil from the primary site. The resident ECM composition, however, is also partially responsible for shaping the pre-metastatic niche environment. Therefore, modulating one facet of the TME may not yield to the desirable anti-tumor effects, while the simultaneous targeting of multiple aspects could be a promising strategy. Conclusively, a thorough characterization of TME constituents must be taken prior to any rational design of combinatorial approaches to optimize drug delivery and assure optimal therapeutic responses against metastatic cancer.

References 209

1.
Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
Not in our library10.1016/0092-8674(90)90186-i
2.
Kurose K., Hoshaw-Woodard S., Adeyinka A., Lemeshow S., Watson P.H., Eng C. Genetic model of multi-step breast carcino-genesis involving the epithelium and stroma: Clues to tumour-microenvironment interactions. Hum. Mol. Genet. 2001;10:1907-1913.
Not in our library10.1093/hmg/10.18.1907
3.
Kitamura T., Qian B.-Z., Pollard J.W. Immune cell promotion of metastasis. Nat. Rev. Immunol. 2015;15:73-86.
Not in our library10.1038/nri3789
4.
Dunn G.P., Old L.J., Schreiber R.D. The Immunobiology of Cancer Immunosurveillance and Immunoediting. Immunity. 2004;21:137-148.
Not in our library10.1016/j.immuni.2004.07.017
5.
Eyles J., Puaux A.-L., Wang X., Toh B., Prakash C., Hong M., Tan T.G., Zheng L., Ong L.C., Jin Y., et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J. Clin. Investig. 2010;120:2030-2039.
Not in our library10.1172/jci42002
6.
Paolino M., Choidas A., Wallner S., Pranjic B., Uribesalgo I., Loeser S., Jamieson A.M., Langdon W.Y., Ikeda F., Fededa J.P., et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nat. Cell Biol. 2014;507:508-512.
Not in our library10.1038/nature12998
7.
Bidwell B.N., Slaney C.Y., Withana N.P., Forster S., Cao Y., Loi S., Andrews D., Mikeska T., Mangan N.E., Samarajiwa S.A., et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 2012;18:1224-1231.
Not in our library10.1038/nm.2830
8.
McAllister S.S., Weinberg R.A. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat. Cell Biol. 2014;16:717-727.
Not in our library10.1038/ncb3015
9.
Neophytou C.M., Pierides C., Christodoulou M.I., Costeas P., Kyriakou T.C., Papageorgis P. The Role of Tumor-Associated My-eloid Cells in Modulating Cancer Therapy. Front. Oncol. 2020;10:899.
Not in our library10.3389/fonc.2020.00899
10.
Whipple C.A. Tumor talk: Understanding the conversation between the tumor and its microenvironment. Cancer Cell Microenviron. 2015;2:e773.
Not in our library10.14800/ccm.773
11.
Singh S., Mehta N., Lilan J., Budhthoki M.B., Chao F., Yong L. Initiative action of tumor-associated macrophage during tumor metastasis. Biochim. Open. 2017;4:8-18.
Not in our library10.1016/j.biopen.2016.11.002
12.
Smith H.A., Kang Y. The metastasis-promoting roles of tumor-associated immune cells. J. Mol. Med. 2013;91:411-429.
Not in our library10.1007/s00109-013-1021-5
13.
Sanchez L.R., Borriello L., Entenberg D., Condeelis J.S., Oktay M.H., Karagiannis G.S. The emerging roles of macrophages in cancer metastasis and response to chemotherapy. J. Leukoc. Biol. 2019;106:259-274.
Not in our library10.1002/jlb.mr0218-056rr
14.
Wang R., Zhang J., Chen S., Lu M., Luo X., Yao S., Liu S., Qin Y., Chen H. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer. 2011;74:188-196.
Not in our library10.1016/j.lungcan.2011.04.009
15.
Robinson B.D., Sica G.L., Liu Y.-F., Rohan T.E., Gertler F.B., Condeelis J.S., Jones J.G. Tumor Microenvironment of Metastasis in Human Breast Carcinoma: A Potential Prognostic Marker Linked to Hematogenous Dissemination. Clin. Cancer Res. 2009;15:2433-2441.
Not in our library10.1158/1078-0432.ccr-08-2179
16.
Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-Mesenchymal Transitions in Development and Disease. Cell. 2009;139:871-890.
Not in our library10.1016/j.cell.2009.11.007
17.
TGF β Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis · 2015
No notice
18.
Gupta D.K., Singh N., Sahu D.K. TGF-beta Mediated Crosstalk Between Malignant Hepatocyte and Tumor Microenvironment in Hepatocellular Carcinoma. Cancer Growth Metastasis. 2014;7:1-8.
Not in our library10.4137/cgm.s14205
19.
Zhu X.-D., Zhang J.-B., Zhuang P.-Y., Zhu H.-G., Zhang W., Xiong Y.-Q., Wu W.-Z., Wang L., Tang Z.-Y., Sun H.-C. High Expression of Macrophage Colony-Stimulating Factor in Peritumoral Liver Tissue Is Associated with Poor Survival After Curative Resection of Hepatocellular Carcinoma. J. Clin. Oncol. 2008;26:2707-2716.
Not in our library10.1200/jco.2007.15.6521
20.
Lewis C.E., Pollard J.W. Distinct Role of Macrophages in Different Tumor Microenvironments. Cancer Res. 2006;66:605-612.
Not in our library10.1158/0008-5472.can-05-4005
21.
Liu C.Y., Xu J.Y., Shi X.Y., Huang W., Ruan T.Y., Xie P., Ding J.L. M2-polarized tumor-associated macrophages promoted epitheli-al-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab. Investig. 2013;93:844-854.
Not in our library10.1038/labinvest.2013.69
22.
Wang H., Wang X., Li X., Fan Y., Li G., Guo C., Zhu F., Zhang L., Shi Y. CD68(+)HLA-DR(+) M1-like macrophages promote motility of HCC cells via NF-kappaB/FAK pathway. Cancer Lett. 2014;345:91-99.
Not in our library10.1016/j.canlet.2013.11.013
23.
Chu Z., Lai W., Chen S., Wu H., Guan Y., Liu L., Zeng Y., Zhao H., Jiang J. PRL-3 promotes the proliferation of LoVo cells via the upregulation of KCNN4 channels. Oncol. Rep. 2011;26:909-917.
Not in our library10.3892/or.2011.1366
24.
Xu H., Lai W., Zhang Y., Liu L., Luo X., Zeng Y., Wu H., Lan Q., Chu Z. Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner. BMC Cancer. 2014;14:330.
Not in our library10.1186/1471-2407-14-330
25.
CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer · 2015
No notice
26.
Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications · 2019
No notice
27.
A Distinct Macrophage Population Mediates Metastatic Breast Cancer Cell Extravasation, Establishment and Growth · 2009
No notice
28.
Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., Koike M., Inadera H., Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 2000;6:3282-3289.
Not in our library
29.
Saji H., Koike M., Yamori T., Saji S., Seiki M., Matsushima K., Toi M. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer. 2001;92:1085-1091.
Not in our library10.1002/1097-0142(20010901)92:5<1085::aid-cncr1424>3.0.co;2-k
30.
Qian B.-Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475:222-225.
Not in our library10.1038/nature10138
31.
Kitamura T., Qian B.-Z., Soong D., Cassetta L., Noy R., Sugano G., Kato Y., Li J., Pollard J.W. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J. Exp. Med. 2015;212:1043-1059.
Not in our library10.1084/jem.20141836
32.
Chen Q., Zhang X.H.-F., Massagué J. Macrophage Binding to Receptor VCAM-1 Transmits Survival Signals in Breast Cancer Cells that Invade the Lungs. Cancer Cell. 2011;20:538-549.
Not in our library10.1016/j.ccr.2011.08.025
33.
Mesenchymal Stem Cells · 2011
Not checked
34.
Zhou J., Tan X., Tan Y., Li Q., Ma J., Wang G. Mesenchymal Stem Cell Derived Exosomes in Cancer Progression, Metastasis and Drug Delivery: A Comprehensive Review. J. Cancer. 2018;9:3129-3137.
Not in our library10.7150/jca.25376
35.
Atiya H., Frisbie L., Pressimone C., Coffman L. Mesenchymal Stem Cells in the Tumor Microenvironment. Adv. Exp. Med. Biol. 2020;1234:31-42.
Not in our library10.1007/978-3-030-37184-5_3
36.
Yeo R.W.Y., Lai R.C., Zhang B., Tan S.S., Yin Y., Teh B.J., Lim S.K. Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev. 2013;65:336-341.
Not in our library10.1016/j.addr.2012.07.001
37.
Simpson R.J., Lim J.W., Moritz R.L., Mathivanan S. Exosomes: Proteomic insights and diagnostic potential. Expert Rev. Proteom. 2009;6:267-283.
Not in our library10.1586/epr.09.17
38.
Mathivanan S., Fahner C.J., Reid G.E., Simpson R.J. ExoCarta 2012: Database of exosomal proteins, RNA and lipids. Nucleic Acids Res. 2011;40:D1241-D1244.
Not in our library10.1093/nar/gkr828
39.
Lin R., Wang S., Zhao R.C. Exosomes from human adipose-derived mesenchymal stem cells promote migration through Wnt signaling pathway in a breast cancer cell model. Mol. Cell. Biochem. 2013;383:13-20.
Not in our library10.1007/s11010-013-1746-z
40.
Wang M., Zhao C., Shi H., Zhang B., Zhang L., Zhang X., Wang S., Wu X., Yang T., Huang F., et al. Deregulated microRNAs in gastric cancer tissue-derived mesen-chymal stem cells: Novel biomarkers and a mechanism for gastric cancer. Br. J. Cancer. 2014;110:1199-1210.
Not in our library10.1038/bjc.2014.14
41.
Liu K., Li G., Fan C., Diao Y., Wu B., Li J. Increased Expression of MicroRNA-221 in gastric cancer and its clinical significance. J. Int. Med. Res. 2012;40:467-474.
Not in our library10.1177/147323001204000208
42.
Gu H., Ji R., Zhang X., Wang M., Zhu W., Qian H., Chen Y., Jiang P., Xu W. Exosomes derived from human mesenchymal stem cells promote gastric cancer cell growth and migration via the activation of the Akt pathway. Mol. Med. Rep. 2016;14:3452-3458.
Not in our library10.3892/mmr.2016.5625
43.
Wang J., Hendrix A., Hernot S., Lemaire M., De Bruyne E., Van Valckenborgh E., Lahoutte T., De Wever O., Vanderkerken K., Menu E., et al. Bone marrow stromal cell-derived ex-osomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014;124:555-566.
Not in our library10.1182/blood-2014-03-562439
44.
Mesenchymal stem cell-derived extracellular vesicles may promote breast cancer cell dormancy · 2018
Not checked
45.
Neophytou C.M., Kyriakou T.-C., Papageorgis P. Mechanisms of Metastatic Tumor Dormancy and Implications for Cancer Therapy. Int. J. Mol. Sci. 2019;20:6158.
Not in our library10.3390/ijms20246158
46.
Ono M., Kosaka N., Tominaga N., Yoshioka Y., Takeshita F., Takahashi R.-U., Yoshida M., Tsuda H., Tamura K., Ochiya T. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci. Signal. 2014;7:ra63.
Not in our library10.1126/scisignal.2005231
47.
Bliss S.A., Sinha G., Sandiford O.A., Williams L.M., Engelberth D.J., Guiro K., Isenalumhe L.L., Greco S.J., Ayer S., Bryan M., et al. Mesenchymal stem cell–derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res. 2016;76:5832-5844.
Not in our library10.1158/0008-5472.can-16-1092
48.
Puré E., Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: Back to the basics. Oncogene. 2018;37:4343-4357.
Not in our library10.1038/s41388-018-0275-3
49.
Costa A., Kieffer Y., Scholer-Dahirel A., Pelon F., Bourachot B., Cardon M., Sirven P., Magagna I., Fuhrmann L., Bernard C., et al. Fibroblast Heterogeneity and Immunosup-pressive Environment in Human Breast Cancer. Cancer Cell. 2018;33:463-479.e10.
Not in our library10.1016/j.ccell.2018.01.011
50.
Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth · 2015
No notice
51.
Heneberg P. Paracrine tumor signaling induces transdifferentiation of surrounding fibroblasts. Crit. Rev. Oncol. 2016;97:303-311.
Not in our library10.1016/j.critrevonc.2015.09.008
52.
Räsänen K., Vaheri A. Activation of fibroblasts in cancer stroma. Exp. Cell Res. 2010;316:2713-2722.
Not in our library10.1016/j.yexcr.2010.04.032
53.
Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., Sahai E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 2007;9:1392-1400.
Not in our library10.1038/ncb1658
54.
Eck S.M., Cote A.L., Winkelman W.D., Brinckerhoff C.E. CXCR4 and matrix metalloproteinase-1 are elevated in breast carcino-ma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells. Mol. Cancer Res. 2009;7:1033-1044.
Not in our library10.1158/1541-7786.mcr-09-0015
55.
Murphy G., Nagase H. Progress in matrix metalloproteinase research. Mol. Asp. Med. 2008;29:290-308.
Not in our library10.1016/j.mam.2008.05.002
56.
Gonzalez-Avila G., Sommer B., Mendoza-Posada D.A., Ramos C., Garcia-Hernandez A.A., Falfan-Valencia R. Matrix metallo-proteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. Crit. Rev. Oncol. Hematol. 2019;137:57-83.
Not in our library10.1016/j.critrevonc.2019.02.010
57.
Erdogan B., Ao M., White L.M., Means A.L., Brewer B.M., Yang L., Washington M.K., Shi C., Franco O.E., Weaver A.M., et al. Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. J. Cell Biol. 2017;216:3799-3816.
Not in our library10.1083/jcb.201704053
58.
A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer · 2020
Not checked
59.
Rankin E.B., Giaccia A.J. Hypoxic control of metastasis. Science. 2016;352:175-180.
Not in our library10.1126/science.aaf4405
60.
Smolarczyk R., Czapla J., Jarosz-Biej M., Czerwinski K., Cichoń T. Vascular disrupting agents in cancer therapy. Eur. J. Pharmacol. 2021;891:173692.
Not in our library10.1016/j.ejphar.2020.173692
61.
Albrecht I., Christofori G. Molecular mechanisms of lymphangiogenesis in development and cancer. Int. J. Dev. Biol. 2011;55:483-494.
Not in our library10.1387/ijdb.103226ia
62.
Lee E., Fertig E.J., Jin K., Sukumar S., Pandey N.B., Popel A.S. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nat. Commun. 2014;5:1-16.
Not in our library10.1038/ncomms5715
63.
Wang W.-C., Zhang X.-F., Peng J., Li X.-F., Wang A.-L., Bie Y.-Q., Shi L.-H., Lin M.-B. Survival Mechanisms and Influence Factors of Circulating Tumor Cells. BioMed Res. Int. 2018;2018:1-9.
Not in our library10.1155/2018/6304701
64.
Camerer E., Qazi A.A., Duong D.N., Cornelissen I., Advincula R., Coughlin S.R. Platelets, protease-activated receptors, and fi-brinogen in hematogenous metastasis. Blood. 2004;104:397-401.
Not in our library10.1182/blood-2004-02-0434
65.
Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer. 2011;11:123-134.
Not in our library10.1038/nrc3004
66.
Mutoh T., Rivera R., Chun J. Insights into the pharmacological relevance of lysophospholipid receptors. Br. J. Pharmacol. 2012;165:829-844.
Not in our library10.1111/j.1476-5381.2011.01622.x
67.
Tseng J.Y., Yang C.Y., Liang S.C., Liu R.S., Yang S.H., Lin J.K., Chen Y.M., Wu Y.C., Jiang J.K., Lin C.H. Interleukin-17A modulates circulating tumor cells in tumor draining vein of colorectal cancers and affects metastases. Clin. Cancer Res. 2014;20:2885-2897.
Not in our library10.1158/1078-0432.ccr-13-2162
68.
Leblanc R., Houssin A., Peyruchaud O. Platelets, autotaxin and lysophosphatidic acid signalling: Win-win factors for cancer metastasis. Br. J. Pharmacol. 2018;175:3100-3110.
Not in our library10.1111/bph.14362
69.
Frantz C., Stewart K.M., Weaver V.M. The extracellular matrix at a glance. J. Cell Sci. 2010;123 Pt 24:4195-4200.
Not in our library10.1242/jcs.023820
70.
Khawar I.A., Kim J.H., Kuh H.-J. Improving drug delivery to solid tumors: Priming the tumor microenvironment. J. Control. Release. 2015;201:78-89.
Not in our library10.1016/j.jconrel.2014.12.018
71.
Egeblad M., Rasch M.G., Weaver V.M. Dynamic interplay between the collagen scaffold and tumor evolution. Curr. Opin. Cell Biol. 2010;22:697-706.
Not in our library10.1016/j.ceb.2010.08.015
72.
Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., et al. Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling. Cell. 2009;139:891-906.
Not in our library10.1016/j.cell.2009.10.027
73.
Byrne C., Schairer C., Wolfe J., Parekh N., Salane M., Brinton L.A., Hoover R., Haile R. Mammographic Features and Breast Cancer Risk: Effects with Time, Age, and Menopause Status. J. Natl. Cancer Inst. 1995;87:1622-1629.
Not in our library10.1093/jnci/87.21.1622
74.
Boyd N.F., Guo H., Martin L.J., Sun L., Stone J., Fishell E., Jong R.A., Hislop G., Chiarelli A., Minkin S., et al. Mammographic Density and the Risk and Detection of Breast Cancer. N. Engl. J. Med. 2007;356:227-236.
Not in our library10.1056/nejmoa062790
75.
Defining the Role of Solid Stress and Matrix Stiffness in Cancer Cell Proliferation and Metastasis · 2018
No notice
76.
Micro-Environmental Mechanical Stress Controls Tumor Spheroid Size and Morphology by Suppressing Proliferation and Inducing Apoptosis in Cancer Cells · 2009
No notice
77.
Butcher D.T., Alliston T., Weaver V.M. A tense situation: Forcing tumour progression. Nat. Rev. Cancer. 2009;9:108-122.
Not in our library10.1038/nrc2544
78.
Northey J.J., Przybyla L., Weaver V.M. Tissue Force Programs Cell Fate and Tumor Aggression. Cancer Discov. 2017;7:1224-1237.
Not in our library10.1158/2159-8290.cd-16-0733
79.
Samuel M.S., Lopez J.I., McGhee E.J., Croft D.R., Strachan D., Timpson P., Munro J., Schröder E., Zhou J., Brunton V.G., et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and beta-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell. 2011;19:776-791.
Not in our library10.1016/j.ccr.2011.05.008
80.
Lawson C.D., Burridge K. The on-off relationship of Rho and Rac during integrin-mediated adhesion and cell migration. Small GTPases. 2014;5:e27958.
Not in our library10.4161/sgtp.27958
81.
Polacheck W.J., Zervantonakis I.K., Kamm R.D. Tumor cell migration in complex microenvironments. Cell. Mol. Life Sci. 2012;70:1335-1356.
Not in our library10.1007/s00018-012-1115-1
82.
Katsumi A., Orr A.W., Tzima E., Schwartz M.A. Integrins in Mechanotransduction. J. Biol. Chem. 2004;279:12001-12004.
Not in our library10.1074/jbc.r300038200
83.
Shi Q., Boettiger D. A Novel Mode for Integrin-mediated Signaling: Tethering Is Required for Phosphorylation of FAK Y397. Mol. Biol. Cell. 2003;14:4306-4315.
Not in our library10.1091/mbc.e03-01-0046
84.
Kalli M., Papageorgis P., Gkretsi V., Stylianopoulos T. Solid Stress Facilitates Fibroblasts Activation to Promote Pancreatic Cancer Cell Migration. Ann. Biomed. Eng. 2018;46:657-669.
Not in our library10.1007/s10439-018-1997-7
85.
Kalli M., Minia A., Pliaka V., Fotis C., Alexopoulos L.G., Stylianopoulos T. Solid stress-induced migration is mediated by GDF15 through Akt pathway activation in pancreatic cancer cells. Sci. Rep. 2019;9:1-12.
Not in our library10.1038/s41598-018-37425-6
86.
Kalli M., Voutouri C., Minia A., Pliaka V., Fotis C., Alexopoulos L.G., Stylianopoulos T. Mechanical Compression Regulates Brain Cancer Cell Migration Through MEK1/Erk1 Pathway Activation and GDF15 Expression. Front. Oncol. 2019;9:992.
Not in our library10.3389/fonc.2019.00992
87.
Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters · 2014
No notice
88.
Laklai H., Miroshnikova Y.A., Pickup M.W., Collisson E.A., Kim G.E., Barrett A.S., Hill R.C., Lakins J.N., Schlaepfer D.D., Mouw J.K., et al. Genotype tunes pancreatic ductal adeno-carcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat. Med. 2016;22:497-505.
Not in our library10.1038/nm.4082
89.
Jiang H., Hegde S., Knolhoff B.L., Zhu Y., Herndon J.M., Meyer M.A., Nywening T.M., Hawkins T.M.N.W.G., Shapiro I.M., Weaver D.T., et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 2016;22:851-860.
Not in our library10.1038/nm.4123
90.
Stylianopoulos T., Martin J.D., Snuderl M., Mpekris F., Jain S.R., Jain R.K. Coevolution of Solid Stress and Interstitial Fluid Pressure in Tumors during Progression: Implications for Vascular Collapse. Cancer Res. 2013;73:3833-3841.
Not in our library10.1158/0008-5472.can-12-4521
91.
Lu X., Kang Y. Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis. Clin. Cancer Res. 2010;16:5928-5935.
Not in our library10.1158/1078-0432.ccr-10-1360
92.
Hypoxia-regulated target genes implicated in tumor metastasis · 2012
No notice
93.
Stubbs M., McSheehy P.M.J., Griffiths J.R., Bashford C.L. Causes and consequences of tumour acidity and implications for treat-ment. Mol. Med. Today. 2000;6:15-19.
Not in our library10.1016/s1357-4310(99)01615-9
94.
Yang S., Gao H. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharmacol. Res. 2017;126:97-108.
Not in our library10.1016/j.phrs.2017.05.004
95.
Romero-Garcia S., Lopez-Gonzalez J.S., B´ez-Viveros J.L., Aguilar-Cazares D., Prado-Garcia H. Tumor cell metabolism: An integral view. Cancer Biol. Ther. 2011;12:939-948.
Not in our library10.4161/cbt.12.11.18140
96.
Schito L., Semenza G.L. Hypoxia-inducible factors: Master regulators of cancer progression. Trends Cancer. 2016;2:758-770.
Not in our library10.1016/j.trecan.2016.10.016
97.
Dhani N., Fyles A., Hedley D., Milosevic M. The Clinical Significance of Hypoxia in Human Cancers. Semin. Nucl. Med. 2015;45:110-121.
Not in our library10.1053/j.semnuclmed.2014.11.002
98.
Sullivan R., Graham C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007;26:319-331.
Not in our library10.1007/s10555-007-9062-2
99.
Vaupel P., Mayer A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26:225-239.
Not in our library10.1007/s10555-007-9055-1
100.
Preet A., Qamri Z., Nasser M.W., Prasad A., Shilo K., Zou X., Groopman J.E., Ganju R.K. Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non–Small Cell Lung Cancer Growth and Metastasis. Cancer Prev. Res. 2011;4:65-75.
Not in our library10.1158/1940-6207.capr-10-0181
101.
Ravi J., Elbaz M., Wani N.A., Nasser M.W., Ganju R.K. Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway. Mol. Carcinog. 2016;55:2063-2076.
Not in our library10.1002/mc.22451
102.
Pixley F.J., Stanley E.R. CSF-1 regulation of the wandering macrophage: Complexity in action. Trends Cell Biol. 2004;14:628-638.
Not in our library10.1016/j.tcb.2004.09.016
103.
Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: Tumor-associated macrophages as a para-digm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549-555.
Not in our library10.1016/s1471-4906(02)02302-5
104.
Ries C.H., Hoves S., Cannarile M.A., Rüttinger D. CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. Curr. Opin. Pharmacol. 2015;23:45-51.
Not in our library10.1016/j.coph.2015.05.008
105.
Green J.R., Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am. J. Clin. Oncol. 2002;25(Suppl. 1):S3-S9.
Not in our library10.1097/00000421-200212001-00002
106.
Green J.R. Bisphosphonates: Preclinical review. Oncologist. 2004;9(Suppl. 4):3-13.
Not in our library10.1634/theoncologist.9-90004-3
107.
Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach · 2006
No notice
108.
Hiraoka K., Zenmyo M., Watari K., Iguchi H., Fotovati A., Kimura Y.N., Hosoi F., Shoda T., Nagata K., Osada H., et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci. 2008;99:1595-1602.
Not in our library10.1111/j.1349-7006.2008.00880.x
109.
Zhang C., Gao L., Cai Y., Liu H., Gao D., Lai J., Jia B., Wang F., Liu Z. Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model. Biomaterials. 2016;84:1-12.
Not in our library10.1016/j.biomaterials.2016.01.027
110.
Timaner M., Bril R., Kaidar-Person O., Rachman-Tzemah C., Alishekevitz D., Kotsofruk R., Miller V., Nevelsky A., Daniel S., Raviv Z., et al. Dequalinium blocks mac-rophage-induced metastasis following local radiation. Oncotarget. 2015;6:27537-27554.
Not in our library10.18632/oncotarget.4826
111.
Deryugina E.I., Zajac E., Juncker-Jensen A., Kupriyanova T.A., Welter L., Quigley J.P. Tissue-Infiltrating Neutrophils Constitute the Major In Vivo Source of Angiogenesis-Inducing MMP-9 in the Tumor Microenvironment. Neoplasia. 2014;16:771-788.
Not in our library10.1016/j.neo.2014.08.013
112.
Deryugina E.I., Quigley J.P. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: Contrasting, overlapping and compensatory functions. Biochim. Biophys. Acta. 2010;1803:103-120.
Not in our library10.1016/j.bbamcr.2009.09.017
113.
Li X.-Y., Lin Y.-C., Huang W.-L., Hong C.-Q., Chen J.-Y., You Y.-J., Li W.-B. Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells. Med. Oncol. 2011;29:714-720.
Not in our library10.1007/s12032-011-9904-1
114.
Dedes P., Kanakis I., Gialeli C., Theocharis A., Tsegenidis T., Kletsas D., Tzanakakis G., Karamanos N. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease. Biochim. Biophys. Acta (BBA) Gen. Subj. 2013;1830:3625-3634.
Not in our library10.1016/j.bbagen.2013.01.020
115.
Coleman R., Cook R., Hirsh V., Major P., Lipton A. Zoledronic acid use in cancer patients: More than just supportive care? Cancer. 2011;117:11-23.
Not in our library10.1002/cncr.25529
116.
Sun T., Yang Y., Luo X., Cheng Y., Zhang M., Wang K., Ge C. Inhibition of tumor angiogenesis by interferon-gamma by suppression of tumor-associated macrophage differentiation. Oncol. Res. 2014;21:227-235.
Not in our library10.3727/096504014x13890370410285
117.
Choi H.-J., Chung T.-W., Ha K.-T. Luteolin inhibits recruitment of monocytes and migration of Lewis lung carcinoma cells by suppressing chemokine (C–C motif) ligand 2 expression in tumor-associated macrophage. Biochem. Biophys. Res. Commun. 2016;470:101-106.
Not in our library10.1016/j.bbrc.2016.01.002
118.
Guo Z., Xing Z., Cheng X., Fang Z., Jiang C., Su J., Zhou Z., Xu Z., Holmberg A., Nilsson S., et al. Somatostatin Derivate (smsDX) Attenuates the TAM-Stimulated Prolif-eration, Migration and Invasion of Prostate Cancer via NF-kappaB Regulation. PLoS ONE. 2015;10:e0124292.
Not in our library10.1371/journal.pone.0124292
119.
Recent Advances on Drug-Loaded Mesenchymal Stem Cells With Anti-neoplastic Agents for Targeted Treatment of Cancer · 2020
Not checked
120.
Taxol-Loaded MSC-Derived Exosomes Provide a Therapeutic Vehicle to Target Metastatic Breast Cancer and Other Carcinoma Cells · 2019
No notice
121.
Nicolay N.H., Rühle A., Perez R.L., Trinh T., Sisombath S., Weber K.J., Ho A.D., Debus J., Saffrich R., Huber P.E. Mesenchymal stem cells are sensitive to bleomycin treatment. Sci. Rep. 2016;6:26645.
Not in our library10.1038/srep26645
122.
Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal · 2013
No notice
123.
Shimbo K., Miyaki S., Ishitobi H., Kato Y., Kubo T., Shimose S., Ochi M. Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochem. Biophys. Res. Commun. 2014;445:381-387.
Not in our library10.1016/j.bbrc.2014.02.007
124.
Kauer T.M., Figueiredo J.-L., Hingtgen S., Shah K. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat. Neurosci. 2011;15:197-204.
Not in our library10.1038/nn.3019
125.
Uluçkan Ö., Eagleton M.C., Floyd D.H., Morgan E.A., Hirbe A.C., Kramer M., Dowland N., Prior J.L., Piwnica-Worms D., Jeong S.S., et al. APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J. Cell. Biochem. 2008;104:1311-1323.
Not in our library10.1002/jcb.21709
126.
Leblanc R., Lee S.C., David M., Bordet J.C., Norman D.D., Patil R., Miller D., Sahay D., Ribeiro J., Ribeiro P., et al. Interaction of platelet-derived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone. Blood. 2014;124:3141-3150.
Not in our library10.1182/blood-2014-04-568683
127.
Li J., Sharkey C.C., Wun B., Liesveld J.L., King M.R. Genetic engineering of platelets to neutralize circulating tumor cells. J. Control. Release. 2016;228:38-47.
Not in our library10.1016/j.jconrel.2016.02.036
128.
Roy L.D., Sahraei M., Schettini J.L., Gruber H.E., Besmer D.M., Mukherjee P. Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC Cancer. 2014;14:225.
Not in our library10.1186/1471-2407-14-225
129.
Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., et al. Involvement of chemokine receptors in breast cancer me-tastasis. Nature. 2001;410:50-56.
Not in our library10.1038/35065016
130.
Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA. 1998;95:4607-4612.
Not in our library10.1073/pnas.95.8.4607
131.
Stylianopoulos T., Jain R.K. Design considerations for nanotherapeutics in oncology. Nanomedicine. 2015;11:1893-1907.
Not in our library10.1016/j.nano.2015.07.015
132.
Jain R.K., Martin J.D., Stylianopoulos T. The Role of Mechanical Forces in Tumor Growth and Therapy. Annu. Rev. Biomed. Eng. 2014;16:321-346.
Not in our library10.1146/annurev-bioeng-071813-105259
133.
Huang Y., Goel S., Duda D.G., Fukumura D., Jain R.K. Vascular normalization as an emerging strategy to enhance cancer im-munotherapy. Cancer Res. 2013;73:2943-2948.
Not in our library10.1158/0008-5472.can-12-4354
134.
Salgaller M.L. Technology evaluation: Bevacizumab, Genentech/Roche. Curr. Opin. Mol. Ther. 2003;5:657-667.
Not in our library
135.
Chauhan V.P., Stylianopoulos T., Martin J.D., Popović Z., Chen O., Kamoun W.S., Bawendi M.G., Fukumura D., Jain R.K. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 2012;7:383-388.
Not in our library10.1038/nnano.2012.45
136.
Stylianopoulos T., Jain R.K. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc. Natl. Acad. Sci. USA. 2013;110:18632-18637.
Not in our library10.1073/pnas.1318415110
137.
Heist R.S., Duda D.G., Sahani D.V., Ancukiewicz M., Fidias P., Sequist L.V., Temel J.S., Shaw A.T., Pennell N.A., Neal J.W., et al. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc. Natl. Acad. Sci. USA. 2015;112:1547-1552.
Not in our library10.1073/pnas.1424024112
138.
Izumi Y., Xu L., Di Tomaso E., Fukumura D., Jain R.K. Herceptin acts as an anti-angiogenic cocktail. Nat. Cell Biol. 2002;416:279-280.
Not in our library10.1038/416279b
139.
Rosca E.V., Koskimaki J.E., Rivera C.G., Pandey N.B., Tamiz A.P., Popel A.S. Anti-angiogenic peptides for cancer therapeutics. Curr. Pharm. Biotechnol. 2011;12:1101-1116.
Not in our library10.2174/138920111796117300
140.
Zhang B., Shi W., Jiang T., Wang L., Mei H., Lu H., Hu Y., Pang Z. Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy. Oncotarget. 2016;7:62607-62618.
Not in our library10.18632/oncotarget.11546
141.
Jiang W., Huang Y., An Y., Kim B.Y.S. Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. ACS Nano. 2015;9:8689-8696.
Not in our library10.1021/acsnano.5b02028
142.
Sakurai Y., Hada T., Yamamoto S., Kato A., Mizumura W., Harashima H. Remodeling of the Extracellular Matrix by Endothelial Cell-Targeting siRNA Improves the EPR-Based Delivery of 100 nm Particles. Mol. Ther. 2016;24:2090-2099.
Not in our library10.1038/mt.2016.178
143.
Smith N.R., Baker D., Farren M., Pommier A., Swann R., Wang X., Mistry S., McDaid K., Kendrew J., Womack C., et al. Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy. Clin. Cancer Res. 2013;19:6943-6956.
Not in our library10.1158/1078-0432.ccr-13-1637
144.
Tolaney S.M., Boucher Y., Duda D.G., Martin J.D., Seano G., Ancukiewicz M., Barry W.T., Goel S., Lahdenrata J., Isakoff S.J., et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc. Natl. Acad. Sci. USA. 2015;112:14325-14330.
Not in our library10.1073/pnas.1518808112
145.
Size-Tunable Strategies for a Tumor Targeted Drug Delivery System · 2020
Not checked
146.
Stylianopoulos T., Martin J.D., Chauhan V.P., Jain S.R., Diop-Frimpong B., Bardeesy N., Smith B.L., Ferrone C.R., Hornicek F.J., Boucher Y., et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc. Natl. Acad. Sci. USA. 2012;109:15101-15108.
Not in our library10.1073/pnas.1213353109
147.
Stylianopoulos T. The Solid Mechanics of Cancer and Strategies for Improved Therapy. J. Biomech. Eng. 2017;139.
Not in our library10.1115/1.4034991
148.
Stylianopoulos T., Munn L.L., Jain R.K. Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy. Trends Cancer. 2018;4:258-259.
Not in our library10.1016/j.trecan.2018.02.010
149.
Mpekris F., Panagi M., Voutouri C., Martin J.D., Samuel R., Takahashi S., Gotohda N., Suzuki T., Papageorgis P., Demetriou P., et al. Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis. Adv. Sci. 2021;8.
Not in our library10.1002/advs.202001917
150.
Chen I.X., Chauhan V.P., Posada J., Ng M.R., Wu M.W., Adstamongkonkul P., Huang P., Lindeman N., Langer R., Jain R.K. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc. Natl. Acad. Sci. USA. 2019;116:4558-4566.
Not in our library10.1073/pnas.1815515116
151.
Mpekris F., Voutouri C., Baish J.W., Duda D.G., Munn L.L., Stylianopoulos T., Jain R.K. Combining microenvironment normalization strategies to improve cancer immunotherapy. Proc. Natl. Acad. Sci. USA. 2020;117:3728-3737.
Not in our library10.1073/pnas.1919764117
152.
Tsai M., Lu Z., Wientjes M.G., Au J.L.-S. Paclitaxel-loaded polymeric microparticles: Quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics. J. Control. Release. 2013;172:737-744.
Not in our library10.1016/j.jconrel.2013.09.011
153.
Tong R., Chiang H.H., Kohane D.S. Photoswitchable nanoparticles for in vivo cancer chemotherapy. Proc. Natl. Acad. Sci. USA. 2013;110:19048-19053.
Not in our library10.1073/pnas.1315336110
154.
Pietras K., Rubin K., Sjöblom T., Buchdunger E., Sjöquist M., Heldin C.-H., Ostman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002;62:5476-5484.
Not in our library
155.
Mpekris F., Papageorgis P., Polydorou C., Voutouri C., Kalli M., Pirentis A.P., Stylianopoulos T. Sonic-hedgehog pathway inhibition nor-malizes desmoplastic tumor microenvironment to improve chemo-and nanotherapy. J. Control. Release. 2017;261:105-112.
Not in our library10.1016/j.jconrel.2017.06.022
156.
Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science. 2009;324:1457-1461.
Not in our library10.1126/science.1171362
157.
Rhim A.D., Oberstein P.E., Thomas D.H., Mirek E.T., Palermo C.F., Sastra S.A., Dekleva E.N., Saunders T., Becerra C.P., Tattersall I.W., et al. Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2014;25:735-747.
Not in our library10.1016/j.ccr.2014.04.021
158.
Ozdemir B.C., Pentcheva-Hoang T., Carstens J.L., Zheng X., Wu C.C., Simpson T.R., Laklai H., Sugimoto H., Kahlert C., Novitskiy S.V., et al. Depletion of carcinoma-associated fi-broblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719-734.
Not in our library10.1016/j.ccr.2014.04.005
159.
Chen Y., Kim J., Yang S., Wang H., Wu C.-J., Sugimoto H., LeBleu V.S., Kalluri R. Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell. 2021;39:548-565.e6.
Not in our library10.1016/j.ccell.2021.02.007
160.
The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment · 2019
No notice
161.
Tauriello D.V.F., Palomo-Ponce S., Stork D., Berenguer-Llergo A., Badia-Ramentol J., Iglesias M., Sevillano M., Ibiza S., Cañellas A., Hernando-Momblona X., et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538-543.
Not in our library10.1038/nature25492
162.
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade · 2018
No notice
163.
Mariathasan S., Turley S.J., Nickles D., Castiglioni A., Yuen K., Wang Y., Kadel III E.E., Koeppen H., Astarita J.L., Cubas R., et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544-548.
Not in our library10.1038/nature25501
164.
Liu J., Liao S., Diop-Frimpong B., Chen W., Goel S., Naxerova K., Huang Y., Boucher Y., Xu L. TGF-beta blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc. Natl. Acad. Sci. USA. 2012;109:16618-16623.
Not in our library10.1073/pnas.1117610109
165.
De Caestecker M.P., Piek E., Roberts A.B. Role of transforming growth factor-beta signaling in cancer. J. Nat. Cancer Inst. 2000;92:1388-1402.
Not in our library10.1093/jnci/92.17.1388
166.
Chauhan V.P., Martin J.D., Liu H., Lacorre D.A., Jain S.R., Kozin S.V., Stylianopoulos T., Mousa A.S., Han X., Adstamongkonkul P., et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 2013;4:2516.
Not in our library10.1038/ncomms3516
167.
Diop-Frimpong B., Chauhan V.P., Krane S., Boucher Y., Jain R.K. Losartan inhibits collagen I synthesis and improves the dis-tribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. USA. 2011;108:2909-2914.
Not in our library10.1073/pnas.1018892108
168.
Zhao Y., Cao J., Melamed A., Worley M., Gockley A., Jones D., Nia H.T., Zhang Y., Stylianopoulos T., Kumar A.S., et al. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proc. Natl. Acad. Sci. USA. 2019;116:2210-2219.
Not in our library10.1073/pnas.1818357116
169.
Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model · 2021
Not checked
170.
Wilop S., von Hobe S., Crysandt M., Esser A., Osieka R., Jost E. Impact of angiotensin I converting enzyme inhibitors and an-giotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J. Cancer Res. Clin. Oncol. 2009;135:1429-1435.
Not in our library10.1007/s00432-009-0587-3
171.
Keizman D., Huang P., Eisenberger M.A., Pili R., Kim J.J., Antonarakis E.S., Hammers H., Carducci M.A. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur. J. Cancer. 2011;47:1955-1961.
Not in our library10.1016/j.ejca.2011.04.019
172.
Nakai Y., Isayama H., Ijichi H., Sasaki T., Takahara N., Ito Y., Matsubara S., Uchino R., Yagioka H., Arizumi T., et al. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Investig. New Drugs. 2013;31:1294-1299.
Not in our library10.1007/s10637-013-9972-5
173.
Murphy J.E., Wo J.Y., Ryan D.P., Clark J.W., Jiang W., Yeap B.Y., Drapek L.C., Ly L., Baglini C.V., Blaszkowsky L.S., et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase 2 clinical trial. JAMA Oncol. 2019;5:1020-1027.
Not in our library10.1001/jamaoncol.2019.0892
174.
Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner · 2017
No notice
175.
TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity · 2020
No notice
176.
Martin J.D., Panagi M., Wang C., Khan T.T., Martin M.R., Voutouri C., Toh K., Papageorgis P., Mpekris F., Polydorou C., et al. Dexamethasone Increases Cisplatin-Loaded Nanocarrier Delivery and Efficacy in Metastatic Breast Cancer by Normalizing the Tumor Microenvironment. ACS Nano. 2019;13:6396-6408.
Not in our library10.1021/acsnano.8b07865
177.
Pirfenidone normalizes the tumor microenvironment to improve chemotherapy · 2017
No notice
178.
Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages · 2015
No notice
179.
Kim J.H., Shin B.C., Park W.S., Lee J., Kuh H. Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts. Cancer Sci. 2017;108:2470-2477.
Not in our library10.1111/cas.13405
180.
Sherman M.H., Yu R.T., Engle D.D., Ding N., Atkins A.R., Tiriac H., Collisson E.A., Connor F., Van Dyke T., Kozlov S., et al. Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy. Cell. 2014;159:80-93.
Not in our library10.1016/j.cell.2014.08.007
181.
Masterson R., Hewitson T.D., Kelynack K., Martic M., Parry L., Bathgate R., Darby I., Becker G. Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol. Dial. Transplant. 2004;19:544-552.
Not in our library10.1093/ndt/gfg598
182.
Brown E., McKee T., diTomaso E., Pluen A., Seed B., Boucher Y., Jain R.K. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat. Med. 2003;9:796-800.
Not in our library10.1038/nm879
183.
Unemori E.N., Amento E.P. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fi-broblasts. J. Biol. Chem. 1990;265:10681-10685.
Not in our library10.1016/s0021-9258(18)87000-4
184.
Feng S., Agoulnik I.U., Bogatcheva N.V., Kamat A.A., Kwabi-Addo B., Li R., Ayala G., Ittmann M.M., Agoulnik A.I. Relaxin Promotes Prostate Cancer Progression. Clin. Cancer Res. 2007;13:1695-1702.
Not in our library10.1158/1078-0432.ccr-06-2492
185.
Eltahir M., Persson H., Mangsbo S. Tumor localized agonistic anti-CD40 therapy and beyond. Expert Opin. Biol. Ther. 2020;20:215-217.
Not in our library10.1080/14712598.2020.1713084
186.
Khong A., Brown M.D., Vivian J.B., Robinson B.W., Currie A.J. Agonistic anti-CD40 antibody therapy is effective against post-operative cancer recurrence and metastasis in a murine tumor model. J. Immunother. 2013;36:365-372.
Not in our library10.1097/cji.0b013e31829fb856
187.
Gajewski T.F., Schreiber H., Fu Y.-X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013;14:1014-1022.
Not in our library10.1038/ni.2703
188.
O’Hara M.H., O’Reilly E.M., Varadhachary G., Wolff R.A., Wainberg Z.A., Ko A.H., Fisher G., Rahma O., Lyman J.P., Cabanski C.R., et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study. Lancet Oncol. 2021;22:118-131.
Not in our library10.1016/s1470-2045(20)30532-5
189.
Sato-Kaneko F., Yao S., Ahmadi A., Zhang S.S., Hosoya T., Kaneda M.M., Varner J.A., Pu M., Messer K.S., Guiducci C., et al. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017;2.
Not in our library10.1172/jci.insight.93397
190.
Roma-Rodrigues C., Pombo I., Raposo L., Pedrosa P., Fernandes A.R., Baptista P.V. Nanotheranostics Targeting the Tumor Mi-croenvironment. Front. Bioeng. Biotechnol. 2019;7:197.
Not in our library10.3389/fbioe.2019.00197
191.
Ali A., Kataoka N., Ranneh A.-H., Iwao Y., Noguchi S., Oka T., Itai S. Enhancing the Solubility and Oral Bioavailability of Poorly Water-Soluble Drugs Using Monoolein Cubosomes. Chem. Pharm. Bull. 2017;65:42-48.
Not in our library10.1248/cpb.c16-00513
192.
Pettersen E.O., Ebbesen P., Gieling R.G., Williams K.J., Dubois L., Lambin P., Ward C., Meehan J., Kunkler I.H., Langdon S.P., et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: The METOXIA consortium. J. Enzym. Inhib. Med. Chem. 2015;30:689-721.
Not in our library10.3109/14756366.2014.966704
193.
Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer · 2003
No notice
194.
Neri D., Supuran C.T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov. 2011;10:767-777.
Not in our library10.1038/nrd3554
195.
Williams K.J., Gieling R.G. Preclinical Evaluation of Ureidosulfamate Carbonic Anhydrase IX/XII Inhibitors in the Treatment of Cancers. Int. J. Mol. Sci. 2019;20:6080.
Not in our library10.3390/ijms20236080
196.
Ward C., Meehan J., Mullen P., Supuran C., Dixon J.M., Thomas J.S., Winum J.-Y., Lambin P., Dubois L., Pavathaneni N.-K., et al. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. Oncotarget. 2015;6:24856-24870.
Not in our library10.18632/oncotarget.4498
197.
Lou Y., McDonald P.C., Oloumi A., Chia S., Ostlund C., Ahmadi A., Kyle A., Keller U.A.D., Leung S., Huntsman D., et al. Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors. Cancer Res. 2011;71:3364-3376.
Not in our library10.1158/0008-5472.can-10-4261
198.
Wichert M., Krall N. Targeting carbonic anhydrase IX with small organic ligands. Curr. Opin. Chem. Biol. 2015;26:48-54.
Not in our library10.1016/j.cbpa.2015.02.005
199.
Aleman J., Skardal A. A multi-site metastasis-on-a-chip microphysiological system for assessing metastatic preference of cancer cells. Biotechnol. Bioeng. 2019;116:936-944.
Not in our library10.1002/bit.26871
200.
Wang Y., Wu D., Wu G., Wu J., Lu S., Lo J., He Y., Zhao C., Zhao X., Zhang H., et al. Metastasis-on-a-chip mimicking the progression of kidney cancer in the liver for predicting treatment efficacy. Theranostics. 2020;10:300-311.
Not in our library10.7150/thno.38736
201.
Walsh N.C., Kenney L.L., Jangalwe S., Aryee K.-E., Greiner D.L., Brehm M.A., Shultz L.D. Humanized Mouse Models of Clinical Disease. Annu. Rev. Pathol. Mech. Dis. 2017;12:187-215.
Not in our library10.1146/annurev-pathol-052016-100332
202.
Shi C., Chen X., Tan D. Development of patient-derived xenograft models of prostate cancer for maintaining tumor het-erogeneity. Trans. Androl. Urol. 2019;8:519-528.
Not in our library10.21037/tau.2019.08.31
203.
Morton J.J., Bird G., Refaeli Y., Jimeno A. Humanized Mouse Xenograft Models: Narrowing the Tumor–Microenvironment Gap. Cancer Res. 2016;76:6153-6158.
Not in our library10.1158/0008-5472.can-16-1260
204.
Pearson T., Greiner D.L., Shultz L.D. Creation of “humanized” mice to study human immunity. Curr. Protocols Immunol. 2008;15:15-21.
Not in our library10.1002/0471142735.im1521s81
205.
Lefley D., Howard F., Arshad F., Bradbury S., Brown H., Tulotta C., Eyre R., Alférez D., Wilkinson J.M., Holen I., et al. Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts. Breast Cancer Res. 2019;21:130.
Not in our library10.1186/s13058-019-1220-2
206.
Tumor microenvironment differences between primary tumor and brain metastases · 2020
No notice
207.
O’Connell J.T., Sugimoto H., Cooke V.G., Macdonald B.A., Mehta A.I., LeBleu V.S., Dewar R., Rocha R.M., Brentani R.R., Resnick M.B., et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc. Natl. Acad. Sci. USA. 2011;108:16002-16007.
Not in our library10.1073/pnas.1109493108
208.
Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., Macdonald D.D., Jin D.K., Shido K., Kerns S.A., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820-827.
Not in our library10.1038/nature04186
209.
Duda D.G., Duyverman A.M.M.J., Kohno M., Snuderl M., Steller E.J.A., Fukumura D., Jain R.K. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl. Acad. Sci. USA. 2010;107:21677-21682.
Not in our library10.1073/pnas.1016234107

Cited by papers we hold 7

Cancer, metastasis, and the epigenome · 2024
No notice
Role of tumor microenvironment in cancer progression and therapeutic strategy · 2023
No notice
Supercritical fluid extract of Angelica sinensis promotes the anti-colorectal cancer effect of oxaliplatin · 2022
Not checked
Interplay of Helicobacter pylori, fibroblasts, and cancer cells induces fibroblast activation and serpin E1 expression by cancer cells to promote gastric tumorigenesis · 2022
Not checked
Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options · 2022
No notice
Tumor metastasis: Mechanistic insights and therapeutic interventions · 2021
Not checked
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.